## Simon Cervenka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1487006/publications.pdf

Version: 2024-02-01

91 4,621 30 62
papers citations h-index g-index

112 112 7401 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
2	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	7.1	358
3	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain, 2006, 129, 2017-2028.	3.7	224
4	Meta-analysis of cognitive performance in drug-na $\tilde{A}$ -ve patients with schizophrenia. Schizophrenia Research, 2014, 158, 156-162.	1.1	209
5	Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. JAMA Psychiatry, 2019, 76, 739.	6.0	195
6	Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation. Brain, Behavior, and Immunity, 2019, 75, 72-83.	2.0	186
7	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry,the, 2020, 7, 1064-1074.	3.7	149
8	Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3–90 years. Human Brain Mapping, 2022, 43, 431-451.	1.9	143
9	Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychological Medicine, 2018, 48, 82-94.	2.7	121
10	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Research Reviews, 2017, 36, 50-63.	5.0	107
11	Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 173-183.	3.3	106
12	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biological Psychiatry, 2018, 84, 433-442.	0.7	103
13	Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. Neuropsychologia, 2009, 47, 2299-2304.	0.7	94
14	Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28. Molecular Psychiatry, 2017, 22, 850-856.	4.1	94
15	<scp>d</scp> -Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants. JAMA Psychiatry, 2015, 72, 659.	6.0	90
16	Thinking Outside a Less Intact Box: Thalamic Dopamine D2 Receptor Densities Are Negatively Related to Psychometric Creativity in Healthy Individuals. PLoS ONE, 2010, 5, e10670.	1.1	89
17	Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum. NeuroImage, 2013, 67, 1-6.	2.1	88
18	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	2.8	87

#	Article	IF	CITATIONS
19	Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. Acta Psychiatrica Scandinavica, 2017, 135, 439-447.	2.2	80
20	Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3–90 years. Human Brain Mapping, 2022, 43, 452-469.	1.9	72
21	Effects of age, BMI and sex on the glial cell marker TSPO â€" a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	3.3	70
22	Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neurolmage, 2008, 40, 1287-1295.	2.1	65
23	Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Translational Psychiatry, 2012, 2, e120-e120.	2.4	58
24	Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. NeuroImage, 2015, 112, 225-231.	2.1	56
25	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain, Behavior, and Immunity, 2016, 54, 149-157.	2.0	48
26	Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability. NeuroImage, 2010, 50, 323-328.	2.1	44
27	CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Molecular Psychiatry, 2018, 23, 1244-1250.	4.1	44
28	Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7574-7579.	3.3	42
29	A <scp>metaâ€nalysis</scp> of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the <scp>ENIGMA Consortium</scp> . Human Brain Mapping, 2022, 43, 352-372.	1.9	39
30	Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study. NeuroImage, 2014, 102, 590-595.	2.1	37
31	Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain. Neurolmage, 2019, 202, 116143.	2.1	36
32	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient–Control Differences. Biological Psychiatry, 2021, 89, e5-e8.	0.7	36
33	A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxelâ€Based Morphometry. Journal of Neuroimaging, 2012, 22, 28-32.	1.0	35
34	Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder. Translational Psychiatry, 2019, 9, 12.	2.4	35
35	Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Research, 2017, 7, 58.	1.1	33
36	Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Tollâ€like Receptor Stimulation in Peripheral Monocytes. Scandinavian Journal of Immunology, 2016, 84, 262-271.	1.3	32

#	Article	IF	CITATIONS
37	Extrastriatal dopamine D2-receptor availability in social anxiety disorder. European Neuropsychopharmacology, 2017, 27, 462-469.	0.3	31
38	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.1	28
39	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	5.8	26
40	D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. International Journal of Neuropsychopharmacology, 2019, 22, 415-425.	1.0	25
41	Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170156.	1.8	24
42	PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders. Neuroscience Letters, 2019, 691, 26-34.	1.0	23
43	Effects of amphetamine on the human brain opioid system $\hat{a}\in$ a positron emission tomography study. International Journal of Neuropsychopharmacology, 2013, 16, 763-769.	1.0	22
44	Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein. Clinical and Translational Imaging, 2015, 3, 449-460.	1.1	22
45	Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function. EJNMMI Research, 2018, 8, 102.	1.1	21
46	Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390. NeuroImage, 2017, 155, 344-353.	2.1	20
47	Increased number of monocytes and plasma levels of <scp>MCP</scp> â€1 and <scp>YKL</scp> â€40 in firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 432-440.	2.2	20
48	Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Translational Psychiatry, 2021, 11, 566.	2.4	19
49	A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology, 2004, 175, 148-153.	1.5	18
50	Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region. Neurolmage, 2019, 188, 102-110.	2.1	18
51	PET studies of D2â€receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans. Synapse, 2010, 64, 478-485.	0.6	17
52	Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study. Brain, Behavior, and Immunity, 2018, 68, 146-157.	2.0	17
53	First-episode psychosis patients display increased plasma IL-18 that correlates with cognitive dysfunction. Schizophrenia Research, 2018, 195, 406-408.	1.1	15
54	Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography. Journal of Neuroimmunology, 2019, 334, 577000.	1.1	15

#	Article	IF	CITATIONS
55	Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. Nordic Journal of Psychiatry, 2021, 75, 315-322.	0.7	15
56	Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study. Translational Psychiatry, 2017, 7, e1104-e1104.	2.4	14
57	Kinfitr—Âan open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. EJNMMI Research, 2020, 10, 77.	1.1	14
58	Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. EJNMMI Research, 2020, 10, 95.	1.1	13
59	Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. Molecular Psychiatry, 2022, 27, 1233-1240.	4.1	13
60	Age-related diurnal effect on D2 receptor binding: a preliminary PET study. International Journal of Neuropsychopharmacology, 2008, 11, 671-8.	1.0	12
61	Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain. Molecular Psychiatry, 2016, 21, 1077-1084.	4.1	12
62	GRK3 deficiency elicits brain immune activation and psychosis. Molecular Psychiatry, 2021, 26, 6820-6832.	4.1	12
63	Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11C]FLB 457. Neurolmage, 2021, 226, 117523.	2.1	11
64	Meta-analytic studies of the glial cell marker TSPO in psychosis – a question of apples and pears?. Psychological Medicine, 2019, 49, 1624-1628.	2.7	10
65	Nondisplaceable Binding Is a Potential Confounding Factor in <sup>11</sup> C-PBR28 Translocator Protein PET Studies. Journal of Nuclear Medicine, 2021, 62, 412-417.	2.8	10
66	[11C]SCH23390 binding to the D1-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis. EJNMMI Research, 2018, 8, 74.	1.1	9
67	Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis. Scientific Reports, 2021, 11, 7527.	1.6	9
68	Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study. PLoS ONE, 2018, 13, e0193770.	1.1	9
69	Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Molecular Psychiatry, 2022, 27, 3247-3261.	4.1	9
70	Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients. Schizophrenia Research, 2018, 199, 438-441.	1.1	8
71	Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophrenia Research, 2019, 210, 221-227.	1.1	8
72	Synthesis and Preclinical Evaluation of 6-[ <sup>18</sup> F]Fluorine-α-methyl- <scp>l</scp> -tryptophan, a Novel PET Tracer for Measuring Tryptophan Uptake. ACS Chemical Neuroscience, 2020, 11, 1756-1761.	1.7	8

#	Article	IF	Citations
73	Application of positron emission tomography in psychiatryâ€"methodological developments and future directions. Translational Psychiatry, 2022, 12, .	2.4	8
74	Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. PLoS ONE, 2018, 13, e0209584.	1.1	7
75	Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 502-504.	3.3	6
76	Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients. Translational Psychiatry, 2022, 12, .	2.4	6
77	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. Schizophrenia Research, 2019, 208, 490-492.	1.1	5
78	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	0.7	5
79	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5
80	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. Lecture Notes in Computer Science, 2017, 10541, 371-378.	1.0	4
81	No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis. NPJ Schizophrenia, 2021, 7, 46.	2.0	3
82	Serotonin 5-HT <sub>1A</sub> receptor binding and self-transcendence in healthy control subjectsâ€"a replication study using Bayesian hypothesis testing. PeerJ, 2018, 6, e5790.	0.9	3
83	In response to the letter "[11C]raclopride and extrastriatal binding to D2/3 receptors― NeuroImage, 2020, 207, 116371.	2.1	2
84	Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness. Schizophrenia Research, 2020, 222, 175-184.	1.1	2
85	Objective and Subjective Sleep in Rheumatoid Arthritis and Severe Seasonal Allergy: Preliminary Assessments of the Role of Sickness, Central and Peripheral Inflammation. Nature and Science of Sleep, 2021, Volume 13, 775-789.	1.4	2
86	Molecular Imaging. , 2020, , 145-159.		1
87	Immune sculpting of the psychotic brain? In vivo associations between a glial cell marker and hippocampal morphology. Brain, Behavior, and Immunity, 2018, 74, 43-44.	2.0	0
88	M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY. Schizophrenia Bulletin, 2020, 46, S135-S136.	2.3	0
89	Effects of acute glial cell activation on memory performance $\hat{a}\in$ Implications for treatment of cognitive symptoms in neurological and psychiatric disorders. Brain, Behavior, and Immunity, 2021, 93, 8-9.	2.0	0
90	TSPO Imaging in Psychiatric Disorders. , 2021, , 589-606.		0

#	Article	IF	CITATIONS
91	No evidence for transmission of psychosis, bipolar or depressive disorder via hematopoietic stem cell transplantation: A <scp>Swedish</scp> registry study. Psychiatry and Clinical Neurosciences, 2022, 76, 526-527.	1.0	O